

Webinar on IMI2 – Call 20 topic - Handling of protein drug products and stability concerns

Participant list

31.01.2020

Name	Surname	Organisation	Country	e-mail address	Potential contribution to the project in terms of expertise, resources and activities.
alexandru	arcire	S.c. ARCIRE APPLIED SCIENCE S.r.l.d.	Romania	office-ro@organoid- x.romanian.technolo gy	Trapping and analysis of single cell through dielectrophoresis; Au/Ag nanoparticle biosensors; Drug nanocarrier
Meritxell	Ascanio	BCN Health Economics & Outcomes Reseach S.L.	Spain	meritxell.ascanio@bc nhealth.com	Design and conduct cost-effectiveness analysis, economic evaluations of observational/retrospective data sets, medical writing
Alain	ASTIER	Biopic Pharmaceuticals	France	prof.astier@gmail.co m	More than 15 years experience on the analysis of monoclonal antibodies
Miroslava	Atanassova	Møreforsking Ålesund AS	Norway	miroslava.atanassova @moreforsk.no	Capacity and expertise in investigating stability issues, bioavailability in vitro/ ex vivo and technological properties, etc
Derya	Ayaz	Modis	Belgium	Derya.Ayaz@modisb elgium.be	Project Management/Writing Consultancy
SARRA	BEN ATTIA	Luxembourg Institute of Health	Luxembourg	sarra.benattia@lih.lu	NA
Jonathan	Bones	NIBRT	Ireland	jonathan.bones@nib rt.ie	Advanced analytical characterization of biologics for stability assessment, training.

Name	Surname	Organisation	Country	e-mail address	Potential contribution to the project in terms of expertise, resources and activities.
Beate	Boulgaropoulos		Austria	Beate.Boulgaropoulos@joanneum.at	Expertise in investigation of PK and PD of drugs ex vivo, in vivo in clinical studies with Open Flow Microperfusion
Jennifer	Byrne	NIBRT	Ireland	jennifer.byrne@nibrt.ie	NIBRT research teams provide in depth understanding of the challenges and opportunities around the manufacture of biologics
Jennifer	Camaradou		United Kingdom	jenniferccamaradou@gmail.com	EU project expertise
Margarida	Corominas	Institute for Research in Biomedicine (IRB Barcelona)	Spain	clara.caminal@irbbarcelona.org	IRB addresses fundamental biological questions around Cancer Science, Aging and Metabolism, and Mechanisms of Disease
Francis P.	Crawley	GCPA & SIDCER	Belgium	fpc@gcpalliance.org	Member, IMI Pool of Patient Experts. Ethics Advisor and/or Data Protection Officer on IMI(1&2) and European Commission Projects
Mirjam	Crul	Amsterdam UMC	Netherlands	m.crul@amsterdamumc.nl	Experience in drug stability studies and in handling procedures of protein drugs in health care facilities and home treatment
Giorgia	De Paoli	University of Dundee	United Kingdom	gdepaoli@dundee.ac.uk	I am a research pharmacist and pharmaceutical chemist specialized in the manufacture and control of clinical trial material.

Name	Surname	Organisation	Country	e-mail address	Potential contribution to the project in terms of expertise, resources and activities.
Jon	de Vlieger	Lygature	Netherlands	jon.devlieger@lygature.org	consortium management and coordination
Katarzyna	Derwinska	Wpd Pharmaceuticals		katarzyna.derwinska@wpdpharmaceuticals.com	we are workin on the recombinant protein drugs for the treatment of GBM.
Mara	Diaconu	Norwegian University of Science and Technology, Faculty of Medicine and Health Sciences	Norway	mara.diaconu@ntnu.no	Expertise in IMI, leading research in field, clinical trials, HUNT study data and other data set
Anke	Dienelt			dienelt@4teen4.de	protein drug product development
Antonia	Diukendjjeva			antonia.diukendjjeva@imresearch.co	Clinical Trial Services, Validation Services, Medical Writing and Editing
Bernard	Do			bernard.do2@gmail.com	Stability studies
Ulla	Elofsson	RISE Research Institutes of Sweden	Sweden	ulla.elifsson@ri.se	Formulation science, characterisation of biologics, stability in solution, coordination
Anne-Laure	Fize	IUCT-Oncopole	France	fize.annelaure@iuct-oncopole.fr	Not applicable

Name	Surname	Organisation	Country	e-mail address	Potential contribution to the project in terms of expertise, resources and activities.
robert	forbes	university of central lancashire	United Kingdom	rtforbes@uclan.ac.uk	professor with expertise in protein aggregation and industry network to develop aggregation instruments
Marco	Fragai	University of Florence and Magnetic Resonance Center (CERM)	Italy	fragai@cerm.unifi.it	NMR methods for "higher order structure" assessment of biologics; Expression of isotopically enriched proteins
Jonas	Fransson	Swedish Orphan Biovitrum	Sweden	jonas.fransson@sobi.com	We would bring products and associated knowledge, methods, We would also bring logitics system and some clinical experience
Anna	Fureby	RISE Research Institutes of Sweden	Sweden	anna.fureby@ri.se	formulation, characterisation, physical chemistry, advanced instrumentation, innovation, intersectorial collaboration
LATE GOURANGA	GHOSH	TATA CUMMINS LTD AMS	India	kanan_2022@rediffmail.com	DR.SUMIT GHOSH. MBBS. M.D. CMRI HOSPITAL . KOLKATTA INDIA
Seyda	Gokturk		Turkey	seydapirincci@gmail.com	I've worked with proteins for 7 years and I believe that i can contribute to the discussions about its stability
Noreen	Grünauer	RCPE GmbH	Austria	noreen.gruenauer@rcpe.at	Improve protein drug production development processess (tools&methods to improve DB robustness, determination of critical parame

Name	Surname	Organisation	Country	e-mail address	Potential contribution to the project in terms of expertise, resources and activities.
Christopher	Hardt	LifeGlimmer GmbH	Germany	hardt@lifeglimmer.com	Data preprocessing, standardization & integration, Machine learning, Omics analysis, Text mining, App development
Harri	Härmä	QRET Technologies Ltd	Finland	harri.harma@utu.fi	New technology for protein stability, degradation and aggregation - 50-fold improved sensitivity compared to existing techniques
Claire	Hope	CPI	United Kingdom	claire.hope@uk-cpi.com	Biologics manufacturing process development; protein drug product analysis/formulation/delivery; smart packaging technology
Sibel	Kalyoncu Uzunlar	Izmir Biomedicine and Genome Center	Turkey	sibel.kalyoncu@ibg.edu.tr	We try to improve biophysical properties of antibody fragments for therapeutic and diagnostic applications
Murat	Karadağ	izmir Biomedicine and Genome Center/Institute	Turkey	murat.karadag@msfr.ibg.edu.tr	Development of aggregation-resistant antibody fragments
Nina	Khristenko	European Institute of Chemistry and Biology	France	nina.khristenko@inserm.fr	Characterizing the folding of recombinant therapeutic protein using mass spectrometry based techniques like HDX, ion mobility

Name	Surname	Organisation	Country	e-mail address	Potential contribution to the project in terms of expertise, resources and activities.
Maryse	Letiembre	Institute for Research in Biomedicine (IRB)	Switzerland	maryse.letiembre@irb.usi.ch	Experience in modifying the handling and product conditions to improve stability of protein DP
Selma	Mautner			selma.mautner@joanneum.at	protein binding research
Albert	Mihrianyan	Uppsala University	Sweden	albert.mihrianyan@angstrom.uu.se	Nanotechnology, bioprocessing, separation and purification science; materials characterisation; biologics formulation
Constanza	Niell	DiabetesCERO	Spain	constanzaniell@gmail.com	I am a carer of my daughter with Diabetes T1. I am an EC Independent Expert in areas other than DT1. Resourceful and proactive.
Iulia	Oita	Ablynx	Belgium	iulia.oita@ablynx.com	Stability expertise for both small and large molecules (proteins)
Alexis	Oliva Martín	University of La Laguna	Spain	amoliva@ull.es	I have many experience (around 20 years) in stability studies using protein drug product.
Claudia	Pfander	ARTTIC SAS	Germany	pfander@arttic.eu	long-standing consultancy expertise with respect to IMI proposal development and project management service
Isabelle	Philippe	CEA	France	isabelle.philippe@cea.fr	protein engineering
Muriel	Priault	CNRS	France	muriel.priault@ibgc.cnrs.fr	expertise to measure protein stability and screen for products that slow down protein degradation

Name	Surname	Organisation	Country	e-mail address	Potential contribution to the project in terms of expertise, resources and activities.
Nevena	Radisavljevic		Italy	nradisavljevic@gmail.com	innovative insight
Rofagha	Rofagha	Schuttelaar & Partners	Belgium	bea.rofagha@gmx.net	Societal impact studies, communication expertise (incl. strategy, website, videos, events, social media), project management
Viviana	Roman	Institute of Virology-Center of Immunology	Romania	rviviana30@yahoo.com	Molecular Biology, patients samples, networking
nir	shaled	ISERD	Israel	nir.s@iserd.org.il	NCP
tale.sliedrecht@lygature.org	Sliedrecht	Lygature	Netherlands	tale.sliedrecht@lygature.org	Programme management
Hugo	Soares	iBET	Portugal	hsoares@ibet.pt	iBET has cumulative experience in developing bioprocesses for the GMP-production / GMP-analytics GMPpurification of biomolecules
Roisin	Thompson	Centre for Process Innovation	United Kingdom	roisin.thompson@uk-cpi.com	CPI is a UK RTO with capabilities in biologics process development, formulation & material science and sensors & electronics
Marco	van de Weert	University of Copenhagen	Denmark	marco.vandeweert@sund.ku.dk	Expertise in protein analytics and formulation, with special emphasis on physical stability.
Alessandra	Veronese	Accademia dei Pazienti (EUPATI Italy)	Italy	veronal2710@gmail.com	I can bring my expertise either as Expert Patient EUPATI Italy, or as Clinical Research Expert with 20 years of experience

Name	Surname	Organisation	Country	e-mail address	Potential contribution to the project in terms of expertise, resources and activities.
Marie	Wahlgren	Lund University	Sweden	marie.wahlgren@food.lth.se	We have started to build up knowledge on protein and excipient interaction in solution as well as characterisation of colloidal
mathias	winterhalter	Jacobs University Bremen	Germany	m.winterhalter@jacobs-university.de	Biophysics of protein stability
Ursula	Wirtz	ConsulTech GmbH	Germany	wirtz@consultech.de	support in the administrative grant process, proposal writing, grant- and projectmanagement
Emre	YARCI	Association of Research-Based Pharmaceutical Companies (AIFD)	Turkey	emre.yarci@aifd.org.tr	Network facilitation
ilker	Yeşilkaya	DNB (Decision & Behaviour Analytics LLC.	Turkey	ilkeryesilkaya@dnbanalytics.com	AI- based clinical behavioral research platform focused on psychiatric disorders
Berry	Zhao	UK Köln	Germany	yue.zhao@uk-koeln.de	Individualised therapy for GI Cancer
Liga	Zvejniece	Latvian IOS	Latvia	liga@farm.osi.lv	Analysing both animal and human samples, analytical chemistry (UPLC/MS), pharmacokinetic (PK/PD). Animal behaviour studies.